Accutar Biotechnology
Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies
CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intel...
- 2 years ago
Accutar Biotechnology Announces First Patient Dosed in China with AC0176 in Phase 1 Study in Prostate Cancer
CRANBURY, N.J. & SHANGHAI — Accutar Biotechnology, Inc., a clinical stage biotechnology company fo...
- 2 years ago
Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies
CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intel...
- 2 years ago
Accutar Biotechnology Announces First Patient Dosed in China with AC0682 in Phase 1 Study in ER-Positive Breast Cancer
CRANBURY, N.J. & SHANGHAI — Accutar Biotechnology, Inc., a clinical stage biotechnology company fo...
- 2 years ago
Accutar Biotechnology Announces Fast Track Designation Granted by FDA to AC0176 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
BROOKLYN, N.Y. - Accutar Biotechnology, Inc., a clinical stage biotechnology company focusing on art...
- 3 years ago
